Tirzepatide Boca Raton: What the Zepbound Label and Trials Record

Most of what is written about tirzepatide Boca Raton patients find online quotes a single headline number and leaves out which trial it came from, who was in that trial, and what happened afterwards. The approved labeling contains all three, for four separate trials, and it is a more useful thing to read before a consultation than any before-and-after gallery. This page is built from it.

Tirzepatide Boca Raton: what the FDA actually approved

Tirzepatide is sold for weight management under the brand name Zepbound. The approved indication is worth reading in full, because the wording is narrower than the way the drug is usually discussed. The label states it is indicated “in combination with a reduced-calorie diet and increased physical activity” to “reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition”.

Two things follow from that sentence. The first is that diet and activity are inside the indication rather than alongside it, which is why a serious programme asks about what you eat and how you move before it asks anything else. The second is the phrase maintain weight reduction long term. This is approved as a long-term treatment, and the trial that tested stopping it is discussed further down this page.

A second indication was added for sleep: “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity”. That was evaluated in two 52-week placebo-controlled trials enrolling 469 patients in total, in people with an apnea-hypopnea index of 15 or above and a BMI of 30 or above. If you have been told you have sleep apnoea, that is worth raising at consultation, because it changes the conversation.

Like every medicine in this class, tirzepatide carries a boxed warning about the risk of thyroid C-cell tumours, based on findings in rats, with the relevance to humans not established. It is reviewed with you, along with your history and anything you already take, before a prescription is considered. It is not a treatment everyone is a candidate for, and a consultation that does not say so is not doing its job.

What the four trials recorded, and why the numbers differ

The label reports four weight-management trials. They produced noticeably different results, and the reason is who was enrolled in each. Reading them side by side is the fastest way to understand what to expect.

Study 1 is the headline trial and the one most pages quote. Study 2 enrolled people who also had type 2 diabetes, and the results are several percentage points lower at the same dose. That pattern is consistent across this class of medicine and it is not a failure of the drug; it is the reason a programme should know your metabolic picture before it sets an expectation.

Study 3 is the one worth sitting with. Everyone in it had already completed twelve weeks of intensive lifestyle intervention before randomisation. In the 72 weeks that followed, the placebo group gained 2.5% while the treated group lost 18.4%. It is the clearest evidence in the label that this is not a substitute for the work, and also that the work alone did not hold.

The gastrointestinal effects are the ones most people notice. The label lists nausea, diarrhoea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, eructation, hair loss and reflux among reactions occurring in at least 5% of patients, with nausea reported in 8% to 28% across dose groups and diarrhoea in 8% to 23%. Most of it clusters around dose increases, which is the argument for escalating slowly rather than chasing the top dose.

The trial that tested stopping, and what it found

This is the part of the record that most weight loss marketing leaves out, and it is the single most useful thing to understand before starting.

Study 4 ran differently from the others. Every participant took tirzepatide openly for 36 weeks first. Then 670 of them were randomised either to keep going or to switch to placebo for another 52 weeks. The group that continued lost a further 5.5%. The group that stopped gained 14.0%.

That result is why the approved indication includes the words maintain weight reduction long term, and why any honest programme talks about the second year at the first appointment rather than the twelfth. A medication that works while it is taken and reverses when it is not is a chronic treatment, in the same way blood pressure medicine is, and it should be planned like one.

It also shapes what the rest of the programme is for. The months on treatment are the window in which eating patterns, protein intake, resistance training and sleep can actually be changed, because appetite is no longer fighting every one of those changes. What is built during that window is what remains available afterwards. Nothing in the label promises that lifestyle work prevents the regain measured in Study 4 — that was not tested — but it is the part of the plan you keep.

How the dose is built, and why it is not a menu

The label sets out one schedule. Treatment starts at 2.5 mg once weekly for four weeks, a dose the label describes as a starting dose rather than a treatment dose. Increases are then made “in 2.5 mg increments, after at least 4 weeks on the current dose”. Maintenance doses for weight reduction are 5 mg, 10 mg or 15 mg, and 15 mg is the maximum.

Two points matter more than the numbers. The first is that 5 mg is a maintenance dose in its own right, not a staging post — it recorded a 15.0% mean reduction over 72 weeks in Study 1. Plenty of people do well and stay there. The second is that the four-week minimum between increases exists because that is how the trials were run; moving faster is not supported by the data the approval rests on.

Where you settle is a clinical decision made with you, against how you are responding, what side effects you are having and what else is going on in your health. It is not a number chosen in advance, and it is not decided by what someone else in your life is taking.

Tirzepatide is a prescription medicine. Whether it is appropriate at all, and at what dose, is determined at a medical consultation that includes your history, your current medications and the boxed warning above. This page is written to tell you what the approved labeling says, so that the consultation starts from the same place you do.

Tirzepatide in Boca Raton: how the programme runs at Brazelia MedSpa

A weekly injection is the smallest part of this. What decides how the year goes is what is measured, how often you are actually seen, and whether anyone notices when something is drifting.

The programme is built around review rather than refills. Weight is one measure among several, because a reduction of the size these trials report takes lean mass with it if nothing is done about protein and resistance training. That is why body composition, not the number on the scale, is the more useful thing to track, and why nutrition and training sit inside the programme rather than beside it.

Because Brazelia MedSpa runs hormone, metabolic and skin programmes in the same building, the questions that come up during a large weight reduction have somewhere to go. Thyroid and metabolic labs, sleep, the skin laxity that often follows, and the plan for maintaining a result once the target is reached are all handled by the same team rather than referred out and forgotten.

Tirzepatide is one of two medicines used here for this purpose, and it is worth knowing it is not strictly a GLP-1 drug at all — the FDA describes it acting at two receptors rather than one. How that difference plays out against semaglutide, and where the compounded copies sold elsewhere now stand, is set out on the GLP-1 weight loss page.

New patients start with a consultation. You will hear what the label supports and what it does not, whether this is a reasonable fit for you, and what a realistic first year looks like — before anything is scheduled or prescribed.

Frequently asked questions

Sources and how this page was built

Every indication, dose, trial size and percentage on this page was read from the Zepbound (tirzepatide) prescribing information, revision 01/2026, on 28 September 2026, and each figure is reported with the trial population it came from. Approved indications are quoted in the FDA’s wording. No figure on this page comes from a manufacturer’s marketing material, and no claim is made about outcomes the labeling does not report.

Why patients choose Brazelia MedSpa

This page is the best answer we can give. Most tirzepatide pages lead with a single percentage and a booking button. This one leads with four trials, their populations and the result of stopping, because that is what the decision actually turns on, and a clinic willing to publish the inconvenient trial is one that will tell you the inconvenient thing in the room.

Weight management at Brazelia MedSpa is run by Khali Reed, CRNA, APRN, in a practice under the medical direction of Dr. Herbert R. Slavin, MD, on site rather than a name on a licence. Prescription weight management is medicine, and it is treated here as medicine rather than as a product.

Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, near Mizner Park, and sees patients from across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. The programme is run by the same people every visit, which matters more on a medication you take for a year than on a treatment you have once.

Weight is also rarely treated as just weight here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, thyroid, sleep, training load and the skin changes that follow a large weight reduction can be looked at in the same place, by people who are already talking to each other.

New patients start with a consultation, and nothing is prescribed on a first visit unless it is clinically appropriate and you want to proceed. You will hear what the label supports, what it does not, and what the plan would look like before anything is decided.

This page describes what published labels, regulatory records and peer-reviewed research report about these treatments. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.